SCHEMBL6492992

SCHEMBL6492992

COONCc1ccc(OC)cc1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
PKM P14618 1/20 0.53
CHRM2 P08172 1/20 0.52
LMNA P02545 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.49
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
RAB9A P51151 1/20 0.49
KMT2A Q03164 1/20 0.49
IDO1 P14902 1/20 0.48
HTT P42858 1/20 0.47
SLC6A4 P31645 1/20 0.47
CASR P41180 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6076678 0.83 ALDH1A1 (0.57) ALDH1A1PKMCHRM2LMNAL3MBTL1
SCHEMBL7955870 0.78 SIGMAR1 (0.50) L3MBTL1MEN1MAPTKMT2AIDO1
SCHEMBL121529 0.78 CHRM2 (0.70) ALDH1A1PKMCHRM2GAAIDO1
SCHEMBL7346729 0.78 ALDH1A1 (0.61) ALDH1A1PKMCHRM2LMNAL3MBTL1
SCHEMBL1608953 0.78 IDO1 (0.53) ALDH1A1PKMCHRM2LMNAL3MBTL1
SCHEMBL4076763 0.78 ALDH1A1 (0.52) ALDH1A1PKMCHRM2LMNAL3MBTL1
Hydrochloric Acid SCHEMBL2147064 0.76 CHRM2 (0.68) ALDH1A1PKMCHRM2GAARAB9A
Hydrochloric Acid SCHEMBL7034100 0.76 ALDH1A1 (0.59) ALDH1A1PKMCHRM2LMNAL3MBTL1
Hydrochloric Acid SCHEMBL9479560 0.76 CHRM2 (0.68) ALDH1A1PKMCHRM2GAARAB9A
SCHEMBL8278372 0.76 IDO1 (0.60) ALDH1A1PKMCHRM2LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6916797-B2 α-arylethylpiperazine derivatives as neurokinin antagonists UCB, S.A. (BE) 2005-07-12 US disclosed
US-20030220323-A1 Alpha-arylethylpiperazine derivatives as neurokinin antagonists UCB, S.A. (BE) 2003-11-27 US disclosed
EP-1242399-A1 $g(a)-ARYLETHYLPIPERAZINE DERIVATIVES AS NEUROKININ ANTAGONISTS UCB S.A. (BE) 2002-09-25 EP disclosed
WO-2001046167-A1 α-ARYLETHYLPIPERAZINE DERIVATIVES AS NEUROKININ ANTAGONISTS UCB, S.A. (BE) 2001-06-28 WO disclosed
EP-1110958-A1 Alpha-arylethylpiperazine derivatives as neurokinin antagonists UCB, S.A. (BE) 2001-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220323-A1 Alpha-arylethylpiperazine derivatives as neurokinin antagonists TACR1, TACR2, NPSR1 ALDH1A1 1102/4885PKM 928/4885CHRM2 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.